Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Silexion Therapeutics Corp

35 indications, side-by-side phase, drug & LoA

$3.13

+0.03 (+0.96%)

Market Cap
2.09 M
EPS
-9.46
P/E Ratio
-
Value Trade
582.79 K
SEC Financials
Q1 2026

  • Dilution Risk

    95%

  • R&D Expenses

    1.37 M

  • Operating CF

    -3.65 M

  • Total Assets

    4.60 M

  • Total Liabilities

    4.31 M

  • Equity

    291.00 K

  • D/E Ratio

    12,345

72.41 %
Week
-50.17 %
1 Month
-68.15 %
3 Month
-80.08 %
6 Month
-99.96 %
5 Year
-99.96 %
All Time
Cash Data
Critical

  • Cash Position

    2.41 M

  • Monthly Burn

    1.22 M

  • Runway

    1.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
36.40 K
52 Week Range
0.23 - 22.36
% held by Insiders
7.36 %
% held by Institutions
1.6 %
Enterprise Value
1.64 M
Total Shares
3.33 M
Short %
39.74 %
Float Shares
2.24 M
Company Description
HQ: 12 ABBA HILLEL ROAD, RAMAT GAN...
Employees:13
https://silexion.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2/3 data readout example
SIL-204 KRAS-driven cancers, pancreatic cancer
Phase 2/3
—
RNA-Based Therapies
Oncology
SIL-204 KRAS-driven cancers, pancreatic cancer
Phase 2/3
—
RNA-Based Therapies
Oncology
SIL-204 KRAS-driven cancers, pancreatic cancer
Phase 2/3
—
RNA-Based Therapies
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
SIL204
KRAS-driven solid tumor cancers,lung cancer,colorectal cancer,pancreatic cancer
Preclinical
2025-07-10
SIL204
KRAS-driven solid tumor cancers,lung cancer,colorectal cancer,pancreatic cancer
Preclinical
2025-07-10
SIL204
KRAS-driven solid tumor cancers,lung cancer,colorectal cancer,pancreatic cancer
Preclinical
2025-07-10
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SLXN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SLXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SLXN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SLXN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SLXN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Silexion Therapeutics Corp (SLXN) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SLXN ranks across every disease it competes in
No competitive intelligence available for SLXN.